Can we break the vicious cycle of VEXAS syndrome?
NCT ID NCT07746986
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study aims to understand how inflammation and the dominance of mutant blood cells drive VEXAS syndrome, a rare and severe autoinflammatory disease. Researchers will analyze blood and bone marrow samples from VEXAS patients and healthy controls to identify key mechanisms and potential targets for new therapies. The goal is to pave the way for treatments that can be given early in the disease, improving outcomes and life expectancy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal new drug targets or repurposed therapies for VEXAS syndrome, potentially improving treatment and prognosis for this rare, severe disease.
- What could go wrong
- This is an observational study, so it won't directly test treatments. The findings may not translate into effective therapies, and the small sample size may limit generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VEXAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale San Raffaele
Milan, MI, 20129, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.